Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868264 · ClinicalTrials.gov registry record · Phase 3
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
A Phase 3 study of Hepatitis C Virus Chronic Infection, sponsored by Atea Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 880
- Enrollment target
- 20
- Study locations
NCT06868264 is a Phase 3 study of Hepatitis C Virus Chronic Infection that is active but no longer recruiting, run by Atea Pharmaceuticals. The registered enrollment target is 880 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT06868264, a Phase 3 study of Hepatitis C Virus Chronic Infection, is active but no longer recruiting, sponsored by Atea Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 880 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Conditions Studied
Interventions
- DRUG Bemnifosbuvir-Ruzasvir (BEM/RZR)
- DRUG Sofosbuvir-Velpatasvir (SOF/VEL)
Study Locations (20)
California
- Atea Study Site - Bakersfield
- Atea Study Site - Coronado
- Atea Study Site - Escondido
- Atea Study Site - Fresno
- Atea Study Site - Long Beach
- Atea Study Site - Los Angeles
- Atea Study Site - Los Angeles
- Atea Study Site - Orange
- Atea Study Site - Pasadena
- Atea Study Site - Sacramento
- Atea Study Site - Torrance
Arizona
- Atea Study Site - Chandler
- Atea Study Site - Flagstaff
- Atea Study Site - Mesa
- Atea Study Site - Phoenix
- Atea Study Site - Phoenix
- Atea Study Site - Tucson
Alabama
- Atea Study Site - Birmingham
- Atea Study Site - Dothan
Arkansas
- Atea Study Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06868264
The ClinicalTrials.gov registry entry for NCT06868264 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 880 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atea Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C Virus Chronic Infection appearing as the primary indexed condition, and to 2 interventions - of which Bemnifosbuvir-Ruzasvir (BEM/RZR) is the first listed.
NCT06868264 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06868264 about?
NCT06868264 is a clinical study titled "C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV". The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
What is the current status of trial NCT06868264?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 2025-04-07. Estimated completion is 2026-12.
What conditions does trial NCT06868264 study?
This clinical trial studies the following conditions: Hepatitis C Virus Chronic Infection.
What interventions are being tested in trial NCT06868264?
The interventions under investigation include: Bemnifosbuvir-Ruzasvir (BEM/RZR) (DRUG), Sofosbuvir-Velpatasvir (SOF/VEL) (DRUG).
Who is sponsoring clinical trial NCT06868264?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868264 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.